Loftware announced that it acquired Prisym ID, a provider of regulated content and label management solutions.
Prisym ID focuses on clinical trials, medical device and pharmaceutical labeling, with the acquisition set to expand Loftware’s enterprise labeling solution offerings for the medical device and pharmaceutical industries while enhancing Loftware’s end-to-end, cloud-based labeling platform with advanced clinical trial leveling and regulated content management capabilities, according to a news release.
Loftware said the acquisition strengthens its ability to meet labeling complexities and evolving regulatory demands, especially amid the COVID-19 pandemic. Building on Prisym ID’s industry focus, Loftware said it will offer customers new levels of innovation to help enable compliance through accurate, validation-ready labeling solutions and regulated product content.
The acquisition will also help address the challenges of clinical trial labeling whether in-house through clinical research organizations (CRO) or clinical development & manufacturing organizations (CDMO).
“This acquisition builds on Loftware’s and Prism ID’s experience and unites the best talent in the medical device and pharmaceutical labeling industry today. Combined, we serve many of the largest global companies with solutions, services and support that are vital to managing labeling complexities and regulatory requirements,” Loftware President and CEO Robert O’Connor Jr. said in the release. “Prisym ID is a pioneer in clinical trials labeling and delivers solutions that are purpose-built for managing the nuances of this space. We will enable customers to tackle the complex challenges around clinical trial labeling and help them with the ability to quickly and efficiently complete trials,” he added.
Loftware said the acquisition enhances medical device and pharmaceutical manufacturers’ ability to deliver certainty and safety to patients with validation and compliance-ready labeling solutions. Customers for both companies will benefit from the increased scale and investment, plus continued innovation and domain expertise, Loftware added.
“Together with Loftware, we can offer new levels of innovation which will further accelerate momentum in serving our customers and market. We’ll also be expanding our global presence and increasing our service and support resources to better serve our customers and meet increasing demands,” Prisym ID CEO Richard Adams said. “By combining the competences of two leaders in the field, we can provide unrivaled solutions for the medical device and pharmaceutical industries, unlock new opportunities in clinical trials labeling and offer a full range of solutions for customers to meet all their labeling needs,” he added.